Sort   by:  
 Page size 
MetabolomicsFuzheng Jiedu Xiaoji Formula Enhances Anti-PD-1 Therapy for Hepatocellular Carcinoma by Inhibiting Regulatory T Cell Lipotoxicity

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
MetabolomicsHypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase Inhibitor JAS239
Background: Elevated choline kinase alpha (ChoK) levels are observed in most solid tumors, including glioblastomas (GBM), and ChoK inhibitors have demonstrated limited efficacy in GBM models. Given that hypoxia is associated with resistance to GBM therapy, we hypothesized that tumor hypoxia c...
2024-06-18 | MTBLS6212 | MetaboLights
MetabolomicsDevelopment of a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var to target glutamine dependency in cancer

The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibito...

2025-08-13 | MTBLS12852 | MetaboLights
TranscriptomicsBulk RNAseq of anti-PD1-induced cardiac dysfunction in C57BL/6J mice
C57BL6/J mice were treated with anti-PD-1 for 2 or 4 weeks, or with isotype control antibody. In echocardiography, cardiac dysfunction was seen both after 2 and 4 weeks, with decreased ejection fraction and left ventricular dilation. Bulk RNA sequencing of the hearts after treatment was performed to...
ORGANISM(S): Mus musculus 
2022-12-03 | E-MTAB-12388 | biostudies-arrayexpress
TranscriptomicsRestoring PD-1 immune checkpoint inhibitor response following IFNγ-driven adaptive resistance
Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by targeting molecules on immune cells that can inhibit the immune system's ability to attack cancer cells. One such checkpoint molecule is PD-1, which is found on the surface of T cells (a type of immune cell) and helps to...
ORGANISM(S): Mus musculus 
2023-08-22 | E-MTAB-12872 | biostudies-arrayexpress
TranscriptomicsEffects of PD-0332991 on gene expression of human pancreatic ductal adenocarcinoma (PDAC) cell lines
PD-0332991 is a small molecule inhibitor for Cdk4 and Cdk6. It exerted growth inhibitory effects on PDAC cell lines (AsPC-1 and COLO-357). Microarray analysis was used to characterize the changes in gene expression profiles of AsPC-1 and COLO-357 upon PD-0332991 incubation AsPC-1 and COLO-357 cells ...
ORGANISM(S): Homo sapiens 
2012-10-10 | E-GEOD-39646 | biostudies-arrayexpress
TranscriptomicsSingle-cell RNAseq of α-PD-1 relapsing YUMM2.1 tumours subsequently treated with PARP14i in vivo
PD-1 signalling blockade is highly effective at restoring immune surveillance and treating melanoma. However, redundant immune homeostatic mechanisms driven by chronic IFNγ signalling can lead to ongoing immune evasion and acquired resistance. PARP14 mediates IFNγ-driven resistance, and prolongs res...
ORGANISM(S): Mus musculus 
2025-01-27 | E-MTAB-14471 | biostudies-arrayexpress
GenomicsPD-1 inhibitor treatment induces gene expression changes at the single-cell level in mouse hearts
PD-1 inhibitor treatment induces gene expression changes at the single-cell level in mouse hearts
PRJNA1200093 | ENA
MetabolomicsThe anticancer human mTOR inhibitor MLN0128/Sapanisertib with potent multistage in vitro antiplasmodium activity and in vivo antimalarial efficacy in a humanised mouse model is an inhibitor of multiple Plasmodium falciparum kinases.
Not available
ORGANISM(S): Plasmodium falciparum 
ST002011 | MetabolomicsWorkbench
Sort   by:  
 Page size